A research team led by a Medical University of South Carolina (MUSC) investigator reports in the May 6 issue of the New England Journal of Medicine that a four-month treatment regimen using rifapentine is effective for treating TB. Shortening the treatment duration is an important step toward increased patient adherence. Read here
Attached below is the updated WHO guidelines which contains a revision of the 6-Month MDR-TB regimen for adults.
Researchers at Washington University School of Medicine in St. Louis have discovered a molecule in the lungs of tuberculosis (TB) patients that reflects the levels of TB-causing bacteria in the lungs,
The much-anticipated rollout of the shorter regimen to treat drug-resistant tuberculosis (TB) has failed to make inroads leaving patients stranded across the country. Having started in March last year